Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone with or without exemestane versus exemestane in ER-positive metastatic breast cancer after nonsteroidal aromatase inhibitor progression
NL-OMON39939Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Abiraterone acetate + prednisone + exemestane with Exemestane (2 arms). Primary endpoints: Progression-free survival and Safety. Started Feb 2012; status: active, not recruiting.
02
Drugs
abirateroneprednisoneexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39939.